Could a common supplement help rare lung disease?

NCT ID NCT05593588

Disease control Sponsor: Avni Joshi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether the supplement fisetin can improve lung disease in people with common variable immunodeficiency (CVID). Twenty participants will receive either fisetin or a placebo on four days over a month. The study measures changes in immune cells and lung function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Fisetin (a plant-based supplement)
What this could lead to: If it works, this could point toward a new treatment for lung scarring in people with CVID.
What could go wrong: This is a small early-phase trial with only 20 participants, so results may not apply widely. Fisetin is a supplement and may not be strong enough to change the disease course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must have received a diagnosis of CVID according to the international consensus document (ICON) at least 30 days before enrollment. * Physician diagnosis of possible GLILD associated with CVID. * IgA results. * Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile. (A negative pregnancy test for women whose menopausal status is determined by self-reported absence of menstrual periods in the past 12 months will be required within 72 hours prior to randomization). * Patient must be able and willing to comply with the requirements of this study protocol. Exclusion Criteria: * Unable or unwilling to give informed consent. * Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial. * Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization. WCBP who are unwilling to abstain from sex or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration. * Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration. * Prisoners, institutionalized individuals, or others who may be considered vulnerable populations, such as individuals with dementia. * Patient currently hospitalized or under immediate consideration for hospitalization. * Current use of tobacco products or as per clinical judgement. * Current excessive caffeine intake (400 mg or more per day).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common variable immunodeficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common variable immunodeficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Common variable immunodeficiency Interstitial lung disease due to systemic disease

Could a common supplement help rare lung disease?

What the study statuses mean